1. Why didn’t the Dow Corning ethics audit program reveal any concerns about the silicone-gel breast implant line?
2. What are the critical factors necessary to make such an ethics audit program work effectively?
3. Was the announcement on March 20 well-advised and ethical?
4. Are there any other ethical dilemmas raised by the case?

On January 6, 1992, the “growing controversy over the safety factor led the U.S. Food and Drug Administration to call for a moratorium on breast implants.”1As January wore on, the crisis deepened until, on January 30, the Tor- onto Globe & Mail carried a New York Times Service report entitled “Dow Corning Fumbles in Damage Control.” Among other critical points, that article stated: